Johnson & Johnson promises 2021 profit jump, vaccine data 'soon'
Johnson & Johnson on Tuesday forecast 2021 profit above Wall Street estimates and promised data from its widely watched coronavirus vaccine trial soon, as the healthcare conglomerate races to develop a potential single-dose vaccine for COVID-19.
The company had previously signaled that it expected to deliver data on the trial before the end of January, at a time when global hopes of defeating the virus are riding on securing adequate supplies of multiple vaccines.
Johnson & Johnson, which runs a large medical device business in addition to its pharmaceuticals unit, forecast 2021 adjusted profit of between $9.40 and $9.60 per share, compared with analysts' estimates of $8.99 per share, according to IBES data from Refinitiv.
The company's fourth-quarter profit fell 56.7% to $1.74 billion. The company reported that it had recorded litigation expenses of $2.9 billion in the fourth quarter.
J&J faces a litany of lawsuits over its marketing of opioids, its pelvic meshes and body powders.
The company's fourth-quarter sales rose to $22.48 billion from $20.75 billion, helped by higher demand for cancer drugs.
Enter your email to get our daily newsletter in your inbox
- Retail buyers continued to purchase gold in India as prices declined to a near one-year low.
- Sensex falls 440 pts to end at 50,405; Nifty ends session in red at 14,938 points
- Companies like Amazon's Prime Video and Netflix are inspecting planned shows and scripts, with some even deleting scenes that could be controversial, five Bollywood directors and producers, and two industry sources said.